Oral THC May Help Some People With Fibromyalgia, but Evidence Remains Limited
A 2023 German study found that oral tetrahydrocannabinol (THC) was associated with greater short-term improvements in pain, depressive symptoms, and quality of life among people receiving inpatient treatment for fibromyalgia. The findings are encouraging, but because the research was retrospective and non-randomized, they do not establish that THC itself caused the improvements.
Published in Schmerz, the study analyzed 120 patients treated in a multidisciplinary pain program between 2017 and 2018. Sixty-two patients—51.7% of the group—received THC alongside the clinic’s broader pain-treatment program, while the remainder did not.
Symptoms improved across the study population during hospitalization. However, the THC-treated group experienced significantly greater improvements in pain intensity, depression scores, and quality of life. Patients receiving THC were also significantly more likely to reduce or discontinue medication in five of the seven analgesic categories examined.
The researchers reported that THC dosing was gradually adjusted over an average of 13.4 days, reaching a mean daily dose of 14.8 milligrams. These details are important because the study evaluated carefully supervised treatment in a specialist setting—not cannabis use in general, and not a single standardized product that can be applied to every patient.
Several limitations temper the results. The treatment was not randomly assigned, so patients who received THC may have differed from those who did not in ways that affected the outcome. The study also took place during an intensive inpatient program, making it difficult to separate the effects of THC from other components of care, such as physical therapy, education, psychological support, and medication changes. Follow-up was limited to the treatment period, so the research does not answer whether benefits persist or whether long-term use is safe.
Other studies have produced similarly promising but preliminary findings. An eight-week, randomized, double-blind trial in Brazil assigned 17 women with fibromyalgia to either a THC-rich cannabis oil or placebo. The cannabis group had a greater reduction in Fibromyalgia Impact Questionnaire scores, although the very small sample limits how broadly the results can be applied. The study is available through PubMed.
A six-month prospective observational study from Israel followed 367 patients using medical cannabis for fibromyalgia. Participants who remained in the study reported lower pain and other symptom improvements, but the study had no randomized control group, meaning that the results may have been influenced by expectations, treatment selection, or other factors. Mild adverse effects included dizziness, dry mouth, and gastrointestinal symptoms. Its findings are also indexed in PubMed.
Overall, the research suggests that cannabinoid-based medicines may help some people with fibromyalgia, particularly when standard treatments have not provided adequate relief. But the evidence is still inconsistent and generally low quality. A 2023 systematic review concluded that available studies support possible short-term pain relief while emphasizing the small number of randomized trials, differences in cannabis products and doses, and limited long-term data.
THC is the primary psychoactive compound in cannabis. It can cause dizziness, drowsiness, dry mouth, impaired coordination, and feelings of intoxication; it may not be appropriate for people with certain psychiatric or substance-use histories. Anyone considering a cannabis-based medicine should discuss product choice, dosing, interactions, and potential risks with a qualified clinician rather than self-treating.
